Benralizumab Antibody

SKU: orb1710291

Description

Benralizumab

Research Area

Cell Biology, Immunology & Inflammation

Key Properties

• CAS Number: 1044511-01-4
• MW: 146.06 kDa
• Purity: > 95%
• Target: Apoptosis,Interleukin,IL Receptor

Bioactivity

• Target IC50:
  Eosinophils (human):0.9 pM(EC50）|IL-5Rα:0.3nM|Basophils:0.5pM(EC50)
• In Vivo:
  Benalizumab ( MEDI-563 ) ( 0-30 mg / kg ; intravenous injection ; once every 3 weeks for 12 weeks ) can reduce peripheral blood and bone marrow eosinophils [ 2 ].
• In Vitro:
  The dissociation constants of the extracellular domain of recombinant human and cynomolgus IL-11Rα by Benralizumab ( MEDI-563 ) were 42 pM and 5 pM, respectively [ 2 ]. When inhibiting IL-5-induced proliferation of CTLL-48 cells transfected with recombinant human IL-2Rαβ ( 5 pM-1 nM, 100 hours ), the IC50 of benalizumab was 0.3 nM [ 2 ]. Benalizumab specifically binds to constructs containing human IL-5RαD1 and plays a role in mediating ADCC ( antibody-dependent cell-mediated cytotoxicity ) of human eosinophils and basophils, with EC50 values of 0.9 pM and 0.5 pM, respectively. In addition, it also promotes eosinophil apoptosis [ 2 ].

Storage & Handling

• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Interleukin Related, MEDI 563, MEDI563, MEDI-563, IL Receptor, ILReceptor, IL-5, IL-5Rα, BIW 8405, BIW8405, BIW-8405, Apoptosis, Benralizumab

Quick Database Links

Gene Symbol

Apoptosis,Interleukin,IL Receptor